STEMdiff™ APEL™2 Medium

Defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages

STEMdiff™ APEL™2 Medium

Defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages

From: 177 USD
Catalog #
05270_C
Defined, animal component-free medium for differentiation of human ES and iPS cells to multiple lineages

Product Advantages


  • Compatible with TeSR™-cultured human ES and iPS cells

  • Compatible with adherent or EB culture differentiation protocols

  • Capable of supporting endoderm, mesoderm and ectoderm differentiation, when specific cytokines or induction factors are added

Overview

STEMdiff™ APEL™ 2 Medium is a fully defined, serum-free and animal component-free medium for the differentiation of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. It is based on the APEL formulation published by Dr. Andrew Elefanty and lacks undefined components such as protein-free hybridoma medium.

STEMdiff™ APEL™ 2 can be used in adherent or embryoid body (EB)-based protocols, such as with AggreWell™. It can be used with a variety of different induction factors or cytokines to support differentiation along ectoderm, mesoderm and endoderm lineages.
Subtype
Specialized Media
Cell Type
Pluripotent Stem Cells
Species
Human
Application
Cell Culture, Differentiation
Brand
STEMdiff
Area of Interest
Drug Discovery and Toxicity Testing, Stem Cell Biology
Formulation
Animal Component-Free, Serum-Free

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05270, 05275
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
05270, 05275
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (15)

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity. H. Zhu et al. Cell stem cell 2020 jun

Abstract

Cytokine-inducible SH2-containing protein (CIS; encoded by the gene CISH) is a key negative regulator of interleukin-15 (IL-15) signaling in natural killer (NK) cells. Here, we develop human CISH-knockout (CISH-/-) NK cells using an induced pluripotent stem cell-derived NK cell (iPSC-NK cell) platform. CISH-/- iPSC-NK cells demonstrate increased IL-15-mediated JAK-STAT signaling activity. Consequently, CISH-/- iPSC-NK cells exhibit improved expansion and increased cytotoxic activity against multiple tumor cell lines when maintained at low cytokine concentrations. CISH-/- iPSC-NK cells display significantly increased in vivo persistence and inhibition of tumor progression in a leukemia xenograft model. Mechanistically, CISH-/- iPSC-NK cells display improved metabolic fitness characterized by increased basal glycolysis, glycolytic capacity, maximal mitochondrial respiration, ATP-linked respiration, and spare respiration capacity mediated by mammalian target of rapamycin (mTOR) signaling that directly contributes to enhanced NK cell function. Together, these studies demonstrate that CIS plays a key role to regulate human NK cell metabolic activity and thereby modulate anti-tumor activity.
Generation of human vascularized brain organoids M. T. Pham et al. NeuroReport 2018

Abstract

The aim of this study was to vascularize brain organoids with a patient's own endothelial cells (ECs). Induced pluripotent stem cells (iPSCs) of one UC Davis patient were grown into whole-brain organoids. Simultaneously, iPSCs from the same patient were differentiated into ECs. On day 34, the organoid was re-embedded in Matrigel with 250 000 ECs. Vascularized organoids were grown in vitro for 3-5 weeks or transplanted into immunodeficient mice on day 54, and animals were perfused on day 68. Coating of brain organoids on day 34 with ECs led to robust vascularization of the organoid after 3-5 weeks in vitro and 2 weeks in vivo. Human CD31-positive blood vessels were found inside and in-between rosettes within the center of the organoid after transplantation. Vascularization of brain organoids with a patient's own iPSC-derived ECs is technically feasible.
Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. P. A. De Sousa et al. Stem cell research 2017 APR

Abstract

A fast track Hot Start" process was implemented to launch the European Bank for Induced Pluripotent Stem Cells (EBiSC) to provide early release of a range of established control and disease linked human induced pluripotent stem cell (hiPSC) lines. Established practice amongst consortium members was surveyed to arrive at harmonised and publically accessible Standard Operations Procedures (SOPs) for tissue procurement

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.